[{"NetIncomeLoss_1_Q1_USD":-15200000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":74700000.0,"DepreciationAndAmortization_1_Q1_USD":17700000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q1_USD":24.62,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q1_USD":4800000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":0.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":0.0,"MarketableSecuritiesCurrent_0_Q1_USD":42100000.0,"PrepaidTaxes_0_Q1_USD":107900000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-200000.0,"StockRepurchasedAndRetiredDuringPeriodShares_1_Q1_shares":0.0,"Liabilities_0_Q1_USD":535200000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":1101200000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":53500000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"AccruedLiabilitiesCurrent_0_Q1_USD":65400000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q1_USD":3300000.0,"InterestPaidNet_1_Q1_USD":2600000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":7300000.0,"FairValueNetAssetLiability_0_Q1_USD":116400000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":124100000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":0.0,"LongTermDebt_0_Q1_USD":224600000.0,"AssetsCurrent_0_Q1_USD":394500000.0,"GoodwillForeignCurrencyTranslationGainLoss_1_Q1_USD":700000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1_Q1_shares":700000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1_Q1_USD":16.4,"StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_0_Q1_USD":110700000.0,"Depreciation_1_Q1_USD":2400000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":17100000.0,"AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_0_Q1_USD":41800000.0,"IncomeTaxesPaid_1_Q1_USD":1300000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-3600000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":118300000.0,"OtherAssetsNoncurrent_0_Q1_USD":1200000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":15300000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-3200000.0,"NumberOfReportableSegments_1_Q1_segment":2.0,"IncomeTaxExpenseBenefit_1_Q1_USD":-28500000.0,"AccountsReceivableNetCurrent_0_Q1_USD":85100000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-1600000.0,"AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue_0_Q1_USD":0.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":-9800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":74700000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":700000.0,"MinorityInterest_0_Q1_USD":0.0,"InvestmentsAndCash_0_Q1_USD":190600000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q1_USD":238200000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q1_USD":23.19,"ResearchAndDevelopmentExpense_1_Q1_USD":17600000.0,"IncreaseDecreaseInOtherNoncurrentAssets_1_Q1_USD":1200000.0,"AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenAmortizedCostBasis_0_Q1_USD":0.0,"CommonStockValue_0_Q1_USD":800000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":-3700000.0,"RepaymentsOfLinesOfCredit_1_Q1_USD":0.0,"OtherReceivablesNetCurrent_0_Q1_USD":2000000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-13600000.0,"MachineryAndEquipmentGross_0_Q1_USD":114100000.0,"IncreaseDecreaseInInventories_1_Q1_USD":-2600000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":18600000.0,"CostsAndExpenses_1_Q1_USD":184800000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q1_USD":-1100000.0,"PaymentForContingentConsiderationLiabilityFinancingActivities_1_Q1_USD":100000.0,"AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_0_Q1_USD":42100000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":-3900000.0,"OtherSundryLiabilitiesNoncurrent_0_Q1_USD":8100000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q1_pure":0.652,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1_Q1_USD":1100000.0,"RevenueRemainingPerformanceObligation_0_Q1_USD":2800000.0,"IntangibleAssetsGrossExcludingGoodwill_0_Q1_USD":829100000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1_Q1_shares":100000.0,"AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_0_Q1_USD":29500000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-600000.0,"DebtInstrumentUnamortizedDiscountNoncurrent_0_Q1_USD":2100000.0,"CommonStockSharesIssued_0_Q1_shares":75200000.0,"GainLossOnDispositionOfAssets_1_Q1_USD":-100000.0,"MarketableSecuritiesNoncurrent_0_Q1_USD":30200000.0,"PaymentsToAcquireProductiveAssets_1_Q1_USD":1500000.0,"BusinessCombinationContingentConsiderationLiabilityCurrent_0_Q1_USD":3300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":74700000.0,"LeaseholdImprovementsGross_0_Q1_USD":32600000.0,"LiabilitiesCurrent_0_Q1_USD":133700000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-59300000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":8400000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":3800000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-43700000.0,"Goodwill_0_Q1_USD":328300000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":1600000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":110000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":1800000.0,"AccountsPayableCurrent_0_Q1_USD":19100000.0,"NonoperatingIncomeExpense_1_Q1_USD":-4100000.0,"InterestExpense_1_Q1_USD":2900000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":36700000.0,"AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_0_Q1_USD":30200000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q1_USD":2600000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q1_USD":75300000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":586100000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_1_Q1_shares":0.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":909300000.0,"IncreaseDecreaseInDeferredIncomeTaxes_1_Q1_USD":-48400000.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_1_Q1_shares":0.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":590900000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":14700000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q1_USD":118300000.0,"IncreaseDecreaseInOtherReceivables_1_Q1_USD":-900000.0,"CapitalizedContractCostGross_0_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":118300000.0,"IncreaseDecreaseInPrepaidTaxes_1_Q1_USD":107900000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":2300000.0,"CommonStockSharesOutstanding_0_Q1_shares":75200000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":17000000.0,"FiniteLivedIntangibleAssetsGross_0_Q1_USD":824300000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1_Q1_USD":13.38,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":32300000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1_Q1_USD":100000.0,"InvestmentIncomeInterest_1_Q1_USD":400000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q1_USD":5900000.0,"InventoryNet_0_Q1_USD":26600000.0,"OperatingIncomeLoss_1_Q1_USD":-39600000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":145200000.0,"CommonStockSharesAuthorized_0_Q1_shares":150000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.01,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.01,"OperatingLeaseRightOfUseAsset_0_Q1_USD":62700000.0,"ShareBasedCompensation_1_Q1_USD":8400000.0,"Assets_0_Q1_USD":1444500000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1_Q1_USD":0.0,"UnrecognizedTaxBenefits_0_Q1_USD":37400000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1444500000.0,"PreferredStockSharesAuthorized_0_Q1_shares":5000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-45400000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-189100000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q1_shares":4700000.0,"TaxesPayableCurrent_0_Q1_USD":3500000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q1_shares":5400000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_1_Q1_USD":-300000.0,"DebtInstrumentCarryingAmount_0_Q1_USD":226700000.0,"StockholdersEquity_0_Q1_USD":909300000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":10700000.0,"ProfitLoss_1_Q1_USD":-15200000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.2,"OperatingLeaseLiabilityCurrent_0_Q1_USD":13600000.0,"ContractWithCustomerRefundLiability_0_Q1_USD":2200000.0,"PropertyPlantAndEquipmentGross_0_Q1_USD":146700000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q1_USD":5200000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":47200000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-13600000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20201109"}]